EGFR and neoplasm: Crosstalk between EGFR and other members of the HER family or unrelated RTKs, as mediated by coexpression of RTKs in the same tumor, neutralize the growth-inhibitory properties of EGFR-targeted therapies due to redundancy in mechanisms of PI3K-AKT and RAS-ERK activation (16–18,36).